Thursday, 19 January, 2012

Cantech Newsletter: Byron Capital’s Douglas Loe says Neptune Technologies is a BUY

Neptune Technologies & Bioressources
TSX: NTB - NASDAQ: NEPT
Basic Shares: 48.2 million
Fully diluted: 53.9 million

*****************************

Yesterday, Nick Waddell’s widely followed Cantech Letter featured an article on Neptune’s recent announcement on 3rd quarter financial results. The article cites Doug Loe’s latest update on Neptune, which maintains a BUY rating and a price target of $6. Doug Loe is a long time proponent of Neptune and Biotech Analyst at Byron Capital Markets.

“…He (Doug Loe) is impressed with Neptune’s progress. Tuesday’s numbers beat his forecast on revenue, which he thought would be $4.85 million, and on EBITDA, which came in at $1.1 million vs. his $0.985 million forecast. Loe also says he sees several “key events” on the horizon that could add value to Neptune.”

To view the Cantech newsletter article, please click here

To view Doug Loe’s January 17, 2012 updated analyst report on Neptune, please click here..

Tuesday, 17 January, 2012

A Summary of Neptune's Conference Call

Neptune Technologies & Bioressources
TSX: NTB - NASDAQ: NEPT
Basic Shares: 48.2 million
Fully diluted: 53.9 million
**************************



At 4:30pm ET today (January 17th), Neptune Technologies held an investor conference call to discuss Q3/F12 quarterly results and to discuss a number to items on the minds of investors.

The call was hosted by Henri Harland, President & CEO of Neptune Technologies & Andre Godin, CFO.

Here’s a summary of the call.

Sherbrooke, Quebec Plant Expansion:
The Company stated Phase I of the plant expansion will cost approximately $14 million.

  • It is expected that $6.5 million of that amount will come from debt financing, $3 million will be covered by an interest-free loan, $2.5 million will be covered by a grant and the remaining $2 million will come from Neptune’s cash flow. Details of the different groups supporting this project will be released as part of a news conference to be held in February or March of this year.
  • The new expansion will include new production capacities and improved extraction technologies, which will increase krill production.
  • Phase I, which is expected to be completed by the first quarter of 2013, will double current plant capacity to 300,000 kg/yr. It will increase to 500,000 kg/yr by the end of Phase II by the end of the following year.

Sales & Marketing:
The Company identified the continuation of expansion in new emerging markets in strategic locations worldwide, the full penetration of the North American market with its nutraceutical products and ensuring that NKO & EKO can be found on the shelves of all major retail stores as the primary focus for the coming months.

  • Neptune has recently increased its sales and marketing team. Sales representatives who now cover South America, Asia and the Middle East. The Company has also hired a Director of Sales exclusively for the United States.
  • During this year Neptune has signed major US distribution deals with companies that represent more than 50% of the Omega-3 dietary supplement market.
  • Neptune has also signed a distribution agreement with the largest supplier dealer in Canada.

Functional foods:
Both Yoplait and the Nestle studies are complete. Neptune has the data, however further analysis is necessary to determine the next steps.

  • For Yoplait, Neptune expects to have to conduct an additional clinical study in order to meet Yoplait’s requirements. Although Neptune has "interesting and positive achievement"; there was a technical mistake made by the European Clinical Research Organization during the recruitment phase of the study. Neptune management is currently in regular communications with Yoplait in order to define the next steps.
  • In regards to Nestle, the analysis of the data is still underway. The results will be made available when Nestle is prepared to disclose them.
  • Neptune expects to provide the market with additional information before or during the summer of 2012.

Chinese JV Partner – SKFC:
Neptune management will be returning to China in February to finalize details with SKFC.

  • The location of the production facility has not yet been determined; however the company is looking at several locations close to Shanghai.
  • Construction of the production facility is expected to begin in late 2012/early 2013.
  • Because SKFC is a Chinese government owned company, Neptune expects minimal complications with roll out and the Company expects to begin seeing revenues in 2014.

Neptune’s R&D Program:
Neptune is currently undertaking clinical studies for “claims” in Europe. In order to be able to make certain health statements on packaging in Europe, those claims need to be supported by specific clinical studies.

  • The company is expecting the clinical study and the regulatory process to be active through 2014.
  • Neptune is also investing in the development of a new marine biomass product, which will include pre-clinical studies. The Company expects to be able to release new data from the new biomass sometime this year.

Patent:
Management summarized the information already public on its US patent covering omega-3 phospholipids.

  • The Company expressed that in regards to the re-examination process currently underway, “As 95% of “inter parties” requests for re-examination are granted, Neptune and its US patent lawyers had anticipated the USPTO’s reactions and the grant. As such, Neptune is well prepared to defend and re-submit all the necessary arguments for the re-examination process and welcome this opportunity to reconfirm the validity of its patent with the US patent Office.
  • Typically the time frame for a re-examination is between 2 to 3 years.
  • Neptune also talked about its recent “Continuation applications” – “These additional protections will not only reinforce Neptune’s position in the US market, but will create an entry barrier to competitors in the krill oil market.
  • Management believes that competitors will have to pay a fee when all of the issues are resolved.

NeuroBioPharm spinoff:
According to management, the Company is committed to providing a dividend of NeuroBioPharm units (shares and warrants) to existing Neptune shareholders.

  • Due to regulatory delays, the process has taken much longer than anticipated.
  • Neptune expects a conclusion to the process in the coming months.

Acasti:
Currently conducting two clinical Phase II studies, one double blind and one open label.

  • The Company expects to be able to publish initial results from the open label clinical study during the coming months.

Q3 Results:
The revenue for the quarter was $5.12 million. This is an increase of 20% compared to the third quarter of fiscal 2011. The increase can be attributed to the global IP strategy in light of the new patent in the United States and infringement cases against competitors. It is also attributed to the new sales force team in place and to the rollout of the Companys NKO and EKO krill oil products in the United States, specifically through its major distribution partners.

  • Neptune krill oils can now be found in Walgreens, Walmarts, CVS Pharmacies and a number of other retailers.
  • After completion of the roll out, Neptune krill products will be available in 20 thousand stores.
  • Neptune’s nutraceutical sales maintained a gross margin of 50%, and recorded a positive EBITDA of $1.1 million and a profit of $900,000.
  • The consolidated group, including Acasti Pharma and NeuroBioPharm resulted in a loss of $1.4 million due in most part to the subsidiaries’ R&D programs, including the Phase II clinical studies that started several months ago in Acasti Pharma. Acasti Pharma and NeuroBioPharm R&D expenses amounted to $3 million for Q3.
  • As the roll-out is recently underway, it is expected Q1/F13 will show accelerated revenues in keeping with the Company’s aggressive North American push. As a result, the Company expects the fourth quarter of fiscal 2012 ending February that the revenues and EBITDA will be at a minimum in the same range as Q3 2012.
  • Neptune’s working capital is over $24 million and its cash on hand over $17 million and also since Neptune nutraceutical is cash flow positive, Neptune has sufficient funds to support all its activities and projects.

The encore version of the conference call will be available tomorrow, January 18, 2012, please visit http://www.neptunebiotech.com/.

Thursday, 12 January, 2012

Acasti Clinical Studies On Track – Watch The Presentation


Acasti Pharma
TSXV: APO
Shares Outstanding: 71.0 million
Fully Diluted: 80.1 million

-------------------------------

Acasti’s presentation is now available to watch online, if you missed it yesterday. Dr. Harlan Waksal, Executive VP for Acasti, delivered a very clear message to conference attendees – Acasti is on track with its Open Label Study and its Phase II Clinical Trial for its Pharma grade krill oil. Data from the Open Label Study will be available in the Spring of this year and data from the Clinical Trial will be available towards the end of this year.

To watch the full video, click here

Wednesday, 11 January, 2012

CORRECTION - Neptune to Hold Conference Call

Neptune Technologies & Bioressources
TSX: NTB - NASDAQ: NEPT
Basic Shares: 48.2 million
Fully diluted: 53.9 million
**************************



In consideration of Martin Luther King Jr. Day, on Monday, January 16, Neptune has decided to move the conference call to Tuesday, January 17. After speaking with a number of key American shareholders, Neptune would like to respect their request to move the call date.

Neptune Technologies and Bioressources Inc. will now be holding a conference call and webcast on Tuesday, January 17, 2012 at 4:30 pm ET.

Main topics to be discussed on the call include:

  • Third quarter and year-to-date financial results,
  • Commercial progress,
  • Plant expansion,
  • IP strategy

Conference call hosts:

  • Henri Harland, President & CEO
  • AndrĂ© Godin, CFO

The webcast can be accessed in listen only mode, free of charge, by clicking the link below:

http://investor.shareholder.com/media/index.cfm?c=ABEA-2FTYUQ&e=2&mediakey=00C91657CB563BC69C078A021724CDA6

To access the conference call by phone within Canada & the U.S. the toll-free number is 1-877-380-5664. Outside Canada and the U.S., dial 1-631-813-4882.

Conference call details:

Conference Topic: Neptune Technologies & Bioressources Conference Call

Conference ID: 42564568

Management will accept questions by telephone during the Q&A period at the end of the presentation. Questions can also be forwarded in advance or during the presentation to f.harland@neptunebiotech.com

An archived recording of the webcast will be available on Neptune's website (www.neptunebiotech.com) two hours after the webcast.

Neptune to Hold Conference Call – Monday, January 16, 2012

Neptune Technologies & Bioressources
TSX: NTB - NASDAQ: NEPT
Basic Shares: 48.2 million
Fully diluted: 53.9 million
**************************



Neptune Technologies and Bioressources Inc. announced today that it will be holding a conference call and webcast on Monday, January 16, 2012 at 4:30 pm ET.

Main topics to be discussed on the call include:

- Third quarter and year-to-date financial results,
- Commercial progress,
- Plant expansion,
- IP strategy

The conference call will be hosted by Henri Harland, President & CEO & André Godin, CFO.

The webcast can be accessed in listen only mode, free of charge, by clicking the link below:

http://investor.shareholder.com/media/index.cfm?c=ABEA-2FTYUQ&e=2&mediakey=00C91657CB563BC69C078A021724CDA6

To access the conference call by phone within Canada & the U.S. the toll-free number is 1-877-380-5664. Outside Canada and the U.S., dial 1-631-813-4882.

Conference call details:

Conference Topic: Neptune Technologies & Bioressources Conference Call
Conference ID: 42564568

Management will accept questions by telephone during the Q&A period at the end of the presentation. Questions can also be forwarded in advance or during the presentation to f.harland@neptunebiotech.com

An archived recording of the webcast will be available on Neptune's website (www.neptunebiotech.com) two hours after the webcast.

Monday, 9 January, 2012

Acasti’s Dr. Harlan Waksal To Present At OneMedForum – You Can Watch It Live!

Acasti Pharma
TSXV: APO
Shares Outstanding: 71.0 million
Fully Diluted: 80.1 million

-------------------------------

This morning Acasti announced that its celebrity Executive Vice President of Business & Scientific Affairs – Dr. Harlan Waksal will be presenting at the San Francisco OneMedForum on Wednesday at 10:15am (PST).

Investors have the opportunity to watch Dr. Waksal present live online, via OneMedTV - http://www.onemedplace.com/forum/presenting-companies/onemedtv

An archive of the event will be available shortly after the presentation on Acasti’s website – http://www.acastipharma.com/

About Dr. Harlan Waksal
Dr. Harlan Waksal was appointed Executive Vice President of Business & Scientific Affairs for Acasti Pharma on July 21, 2011. Dr. Waksal is a physician, co-founder of ImClone System Incorporated and from 1987 to 2003 he held various positions at the company which included serving on the ImClone Board of Directors, Chief Operating Officer and Executive Vice-President, the President and Chief Executive Officer. At ImClone System Dr. Harlan Waksal was instrumental in guiding the development and obtaining FDA approval for a new targeted biologic cancer therapy known as Erbitux. ImClone Systems was acquired by Eli Lily for $6.5 B US in October 2008. Dr. Harlan Waksal currently serves on the Board of Directors of Oberlin College and Senesco Technologies, Inc. He is the author of over 50 scientific publications and has been the inventor of multiple patents and patent applications.

About OneMedForum
Launched in 2008 by OneMedPlace, OneMedForum held in San Francisco runs concurrently with J.P Morgan conference and has rapidly grown in size and stature. More than 1,200 investors and executives attended the OneMedForum San Francisco 2011 conference. OneMedForum New York was launched in 2010 which successfully brought together 74 promising private and microcap healthcare and life science companies with a wide range of investors and strategic partners.

Click here to view the full news release.

Friday, 6 January, 2012

Aeromechanical - The Howard Group Watches From The Sidelines


AeroMechanical Services Ltd. (TSX:V-AMA)
Basic Shares: 118.58 million
Fully Diluted: 134.33 million

***************************************

It is an understatement that there have been a lot of ups and downs with AMA since The Howard Group first signed on in January 2006 to provide the company with investor and financial relations services. While our involvement with AMA through 2011 was a small behind the scenes role, the end of the year saw the formal relationship come to an end.

Our group, which includes the associated Insight Limited Partnership, was introduced to the company in the fall of 2005. We very much liked the technology, the recurring revenue model and the potential but the situation was very high risk, especially in context of AMA's weak financial position. In fact, our initial quarter-million dollar investment before that yearend only took care of some of the company's payables. With some chagrin, the stock then is where it is now, in the low $0.20 range!

Along the way we brought many beneficial relationships to AMA, helped grow the shareholder base by a factor of ten and invested in a series of placements right up to the $1 range. We stayed with the story for the same reasons that it caught the attention of new investors, fund managers and brokers; everyone saw AMA was gaining ground and then there was all that potential! In fact, HG used this period as a case study of how a groundswell of support can be built for a company click here.

A lot of excitement built around the story and it was well through $1 in late 2007, early 2008. The expectation was that AMA would crack China and the order book would rival the flow of the Yangtze River.

Unfortunately, expectation is only good if it is followed with delivery. Once again, the Great Wall kept out the invading hordes. This non-event, AMA's industrial type growth, the economic abyss of 2008, the fall-out of which we continue to live with and a broad retreat from junior stocks has meant that owning the stock has been akin to watching paint dry, the past year in particular. Just over 34 million shares traded in 2011 in a very narrow range of pennies with the average buy price being just under $0.21.

Have we soured on the stock and the company and are going to hit the sell button on a healthy seven figure position now that we are no longer in a formal relationship? Not at all! The actual discussion around the HG halls has been of increasing the ownership position.

To management's credit, the company has been "re-tooled" in terms of how it approaches the business today versus several years ago. In our view, AMA is now a head down - keep grinding attitude company that continues to secure deals for its technology with small and regional airlines while methodically and surgically working to bring a "major" onside.

We don't know when or if AMA will sign an agreement with an international aircraft manufacturer to have its technology become part of the factory offering or if it will finally ink "the" deal in the commercial jet market that would be a major breakthrough or if Chinese airlines will suddenly open the order book in a large way. What we do believe is that AMA has spent at least the last two years making believers of the powers that be of the merits and advantages of its technology. However, will that be enough to "get the deal". As a reminder, it took the inventor of the original black box ten years to see his genius finally make it into a large way into aircraft and that was largely driven by regulation.

We sense that AMA's focus has become acute through the turmoil of the last few years and importantly, there is a balance between expectation and how to get to delivery.We know that many people have wondered why AMA has become so subdued and is noticeably absent from pounding the pavement and tables in North American financial centres.

We've had this chat with CEO and recently re-appointed President, Bill Tempany. He's clear that when AMA decides to once again step into the spotlight, there will be an exceptionally good reason for the decision. We view the approach as realistic and most sensible.

We like good surprises and very much hope that Bill and team deliver the main event early in the new year.

The fact is that with AMA's history as a "stock" and in context of the foreseeable malaise that will linger in the junior markets, it is going to take a material event to break open the dam.

On that note, we wish on behalf of all patient investors the very best to Bill and CFO, Tom French, Tammy, Matt and a host of others at AMA.

We want to see you on centre stage very very soon.

Thursday, 5 January, 2012

Prestigious Medical Journal Publishes Article which Supports Potential New Market for VMS™

VentriPoint Diagnostics Ltd
VPT - TSX Venture
Shares issued: - 102.6 million

Fully diluted: - 134.0 million

*****************************

VentriPoint Diagnostics released news today that independent studies are expanding their product market capabilities.

The VMS™ 3D heart imaging diagnostics system has always been touted as having a broad application among variant heart diseases. Systemic Right Ventricular was the first application chosen by Dr. Shelby Kutty as he sees the simplicity of the VMS™ tool being used for continuous assessment as a therapeutic tool.

Assessment of systemic right ventricular (RV) function is a key point in the follow-up of patients. Current echocardiographic assessment of RV function is at best an estimate, and cardiac magnetic resonance (CMR) is considered the gold standard. However, in management’s view, this technique is expensive, has limited availability, and requires significant expertise to acquire and interpret the images. The VMS™ system for assessment of pulmonary RV function shows promise as a simple yet powerful tool for assessing patients with RV dysfunction of various origins.

We asked the company what the size of this market is?

The response was that singularly (i.e. per patient) this area is a much larger market than blue baby syndrome. However, the key item is the fact that the system would be used on an ongoing basis as it would monitor the success or failure of treatment as treatment usually takes years. The company’s CEO, George Adams comments on this and says: “Note that 47% of patients die from heart failure even with pacemakers. They need more intensive monitoring throughout their life and MRI is too expensive. Existing 3D ultrasound does not have a high enough resolution or window size to be useful when they are dilated and going downhill. VMS™ is perfect to monitor these patients.”

One other point which Dr. Adams comments on is:

“It is interesting that one of the limiting problems in all these studies is the resistance by the patients to undergo another MRI. Basically people hate them and try to avoid them. Since we always have to show the VMS™ is equivalent to MRI, this makes recruiting patients a challenge. Dr. Kutty was very good at talking people into participating. This absolutely reinforces our fundamental value proposition that VMS™ will be better received by the patients and doctors than MRI.”

VentriPoint is clearly on track to proving its Diagnostic promise of better patient health care.... economically.

To view today's news release, please click here.......

Thursday, 22 December, 2011

Carfinco - Stonecap's Top & Only Small Cap Pick For 2012

Carfinco Income Fund
TSX: CFN.UN
Units outstanding: 24.61 million
Units fully diluted: 24.65 million

--------------------------

Jonathan Ratner published a piece today in the Trading Desk section of the Financial Post discussing 6 top picks from Stonecap Securities.

Something Carfinco and its unitholders can be proud of is that Stonecap believes outside of commodities, larger cap companies are more likely to perform than small cap companies with one exception...Carfinco.

“On the commodity front, we remain bullish on all things precious, both silver and gold, while believing that sustained food price inflationary pressure will lift agricultural company share prices as the year progresses,” the firm said. “Beyond commodities we believe larger rather than smaller capitalization stocks will outperform.”

Nonetheless, it included one small-cap non-bank financial that offers “a defendable and highly profitable niche.” That name is Carfinco Income Fund, which buys non-prime consumer loans secured by used automobiles.

Trading at 8.6x Stonecap’s 2012 earnings per unit forecast, the firm believes Carfinco remains an underappreciated story.

“The impressive yield, growth opportunities in future markets, and management’s ability to execute coming out of the credit crisis gives us great confidence about the fund’s prospects for the upcoming year,” analyst Dylan Steuart said in a report. He has a $10 price target on the stock.

Today's full article can be read by clicking here...

Neptune Fires Back On Competitor Over Patent Statements

Neptune Technologies & Bioressources
TSX: NTB - NASDAQ: NEPT
Basic Shares: 48.2 million
Fully diluted: 53.9 million

**************************

Neptune was quick off the mark today with a response to a release issued by its main competitor that the U.S. Patent Office has agreed to a request to re-exam a patent granted to NTB this past October.

Norwegian based, Aker Biomarine & Neptune have been locked in litigation for several years and a sometimes blunt exchange of words.

The patent NTB was granted protects the Omega-3 composition of Neptune Krill Oil(TM) (NKO(R). The patent also “covers amongst others, oils and powders extracted from krill, containing marine phospholipids bonded to EPA and/or DHA, distributed and/or sold in the U.S. market.”

It's not suprising Aker requested the re-examination as should the patent stand, it could impact U.S. sales as well as existing litigation.

Neptune set the tone of its response with the comment that, "Aker has again made statements that are designed to mislead the public about the reexamination process and about the original patent office examination".

To read Neptune's news release, click here.

Wednesday, 21 December, 2011

Pure Nickel - MAN Results 2011

Pure Nickel
(TSX: NIC)(OTCBB: PNCKF)
Basic Shares: 67.8 million
Fully Diluted: 75.5

-----------------------------------------------------



Pure Nickel released results today from its extensive summer drilling program that took place on its massive “blue sky” property called MAN in Alaska.

The company and its joint venture partner ITOCHU completed 11 drill holes totalling 2580 metres, 151 line kilometres of ground magnetometer surveys and 6.9 line kilometres of electromagnetic surveys.

Although the various disciplines of exploration did not land the company and its partner a home run this season, there are several key targets now identified for a follow up year of drilling, potentially next summer.

ITOCHU Corporation of Japan has the ability to earn in up to 75% interest in MAN by incurring $40 million of exploration costs by the end of next year. In total today, it has spent $17 million and earned 30% interest.

There are four distinct areas within MAN which is over 70,000 hectares in total (see attached map) and the company has been aggressively exploring it since 2005. Each short season of exploration has left Pure Nickel and now its partner ITOCHU since 2008, something exciting to go back to. This year, mapping and a portion of the drilling took place on an area that had never been drilled called the Rainy complex. Both grab samples and drill assays at Rainy had showings of platinum group elements or PGE’s including one grab sample with 7.9 grams per tonne PGE and 2% nickel.

A full list of assay results can be viewed on Pure Nickel's web site by clicking here...

In 2010, NIC and ITOCHU discovered what looked to be a reef style PGE mineralization on the Alpha complex which was targeted again this year with three drill holes but assays showed it wasn’t what the partners were looking for.

ITOCHU will have a few months to review the extensive amount of data collected this year at MAN and shareholders will have to keep their fingers crossed that there was enough promising data to warrant further investment at MAN by ITOCHU in 2012.

At time of this posting NIC traded 105,000 shares and is holding its stock price around $0.08. The market is valuing the company roughly at only the cash value it currently has in the bank.

Today's full news release can be viewed by clicking here...